Last Update 17 Feb 26

Fair value Decreased 0.44%

ELV: Medicare Advantage Policy Path Will Support Future Margin Recovery Potential

Analysts have nudged their fair value estimate for Elevance Health slightly lower to $387.85 from $389.55, reflecting recent mixed price target changes and updated views on Medicare Advantage and broader managed care policy risks and opportunities.

Analyst Commentary

Recent research on Elevance Health reflects a mix of optimism about medium term growth drivers and caution around policy and utilization risks, which feeds directly into the modest trim to fair value.

Bullish Takeaways

Bullish analysts lifting price targets into the low to mid US$400s see room for execution on Medicare Advantage and exchanges as a key support for earnings power beyond the near term.
Several research notes describe 2026 as a year when Medicare Advantage could provide meaningful contribution, with some also pointing to healthcare exchanges in 2027 as an additional growth leg.
One firm calls Elevance a top idea for 2026 and views current earnings expectations as a reasonable base, which supports a fair value framework that assumes the company can deliver on its operating plan rather than needing aggressive upgrades.
Updates to targets across managed care peers ahead of Q4 commentary, including a US$413 target and an Outperform view from one major bank, suggest confidence that Elevance can manage utilization trends even if growth in healthcare usage is peaking.

Bearish Takeaways

Bearish analysts trimming price targets, by amounts ranging from US$10 to US$22, highlight uncertainty around Medicare Advantage policy and broader managed care regulation, which can cap how much investors are willing to pay for the stock right now.
A recent downgrade underscores concern that sector wide government policy changes and CMS rate decisions could pressure returns on capital in certain lines of business, even if long term demand for coverage remains intact.
Commentary describing CMS rate actions as a significant negative for managed care and calling a quick insurer recovery after policy calls unlikely shows that not all research desks see a straight path to multiple expansion.
Even some otherwise constructive reports describe government managed care as facing bumps in any recovery path, which helps explain why the consolidated fair value estimate has only been adjusted slightly rather than moving sharply higher.

What's in the News

House Judiciary Committee Republicans issued subpoenas to Elevance and seven other ACA insurers as part of an investigation into potential fraud tied to individual market premium subsidies, adding another policy and oversight thread that investors are watching closely (Axios).
Elevance is among the companies mentioned in coverage of Speaker Mike Johnson signaling that some House Republicans do not want to extend enhanced Affordable Care Act subsidies. This keeps attention on possible changes to exchange affordability and membership trends (Wall Street Journal).
Reports indicate the White House postponed a healthcare proposal that included an extension of Obamacare subsidies after pushback from Congress, with Elevance listed among the insurers that could be affected by any future moves on subsidy policy (MS Now).
Separate coverage describes expectations that the White House could present a framework with a two year extension of Obamacare subsidies and new eligibility limits to address potential premium spikes, again citing Elevance as one of several large publicly traded plans with exposure to ACA markets (Politico).
Media reports highlight a proposal for flat Medicare insurance rates in 2027, which keeps Medicare Advantage reimbursement assumptions in focus for Elevance and other managed care peers as investors track how future CMS decisions may shape returns (Wall Street Journal).

Valuation Changes

Fair Value was trimmed slightly to $387.85 from $389.55, reflecting a modest reset in the base case.
The Discount Rate was nudged up slightly to 6.978% from 6.956%, implying a marginally higher required return on capital.
Revenue Growth was kept essentially unchanged at 1.80% from 1.80%, signaling a steady outlook for top line assumptions in the model.
The Net Profit Margin remained effectively flat at 3.16% from 3.16%, indicating no material shift in expected profitability assumptions.
The Future P/E edged down slightly to 14.66x from 14.71x, pointing to a marginally lower valuation multiple embedded in the updated framework.

16 views

Key Takeaways

Technology investments in analytics, digitization, and AI are boosting efficiency, reducing costs, and improving margin stability across operations.
Expansion into value-based care, behavioral health, and government programs supports revenue growth, earnings diversity, and long-term margin improvement.
Persistent cost pressures, regulatory uncertainty, and integration challenges from acquisitions threaten margin stability, revenue growth, and long-term earnings despite efforts to manage expenses and expansion.

Catalysts

About Elevance Health

Operates as a health benefits company in the United States.What are the underlying business or industry changes driving this perspective?

The company is aggressively leveraging advanced analytics, digitization, and AI-enabled tools to streamline clinical workflows, automate processes, reduce fraud, and improve cost management. These initiatives are expected to lower administrative costs, increase operational efficiency, and gradually stabilize or expand net margins.
Elevance's ongoing expansion of value-based care arrangements, particularly within behavioral health and oncology, and the scaling of risk-based contracts through its Carelon division, position the company to benefit from increased cost predictability, better care coordination, and reduced volatility in medical cost ratios, supporting future margin expansion.
Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.
Demographic shifts, notably the aging U.S. population and increasing chronic disease prevalence, underpin long-term growth opportunities in Medicare Advantage and Medicaid. Elevance's disciplined approach to pricing and rate negotiations, combined with proactive engagement with state partners, is expected to drive sustainable revenue growth and margin recovery in these government-backed segments.
The anticipated market-wide recalibration in ACA and Medicaid following policy changes (e.g., enhanced subsidy expirations, Medicaid redeterminations) is being proactively addressed by Early repricing and data-driven risk adjustment actions. These are likely to restore pricing power and foster margin normalization as utilization stabilizes and state rate updates catch up, supporting future earnings growth.

Elevance Health Earnings and Revenue Growth

Elevance Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Elevance Health's revenue will grow by 6.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 2.8% today to 3.2% in 3 years time.
Analysts expect earnings to reach $7.4 billion (and earnings per share of $33.98) by about September 2028, up from $5.4 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $4.9 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 12.5x on those 2028 earnings, down from 13.2x today. This future PE is lower than the current PE for the US Healthcare industry at 21.0x.
Analysts expect the number of shares outstanding to decline by 2.91% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Elevance Health Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent elevated medical cost trends in both ACA and Medicaid, including higher morbidity and utilization (especially ER visits and behavioral health), are driving up the benefit expense ratio and pressuring both short
and medium-term margins; if these trends persist without sufficient rate increases or effective cost controls, long-term earnings and net margins could remain structurally lower.
Delays and lags in Medicaid rate recovery, with states slow to adjust rates even as member acuity and utilization rise post-redetermination, could result in a prolonged period of under-compensated risk, dragging on operating margins and limiting revenue growth despite constructive negotiations.
The possible expiration of enhanced ACA subsidies and the implementation of Medicaid work requirements, as well as ongoing and potential future regulatory and policy changes, introduce significant uncertainty to risk pools and membership; this could cause further deterioration in revenue stability and risk higher costs without commensurate premium increases.
Elevated levels of aggressive and potentially inappropriate provider coding-sometimes amplified by new AI-assisted tools and manipulation of IDR processes-are increasing claims costs and inflating allowed amounts, presenting an ongoing risk to cost containment efforts and negatively impacting medical loss ratios and profitability.
Integration risk and margin pressure from recent and ongoing acquisitions in Carelon (including CareBridge and specialty pharmacy), where rapid top-line growth is coupled with margin dilution and execution risk, could dampen expected improvements in earnings diversity and structural operating leverage.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $370.444 for Elevance Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $507.0, and the most bearish reporting a price target of just $297.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $230.4 billion, earnings will come to $7.4 billion, and it would be trading on a PE ratio of 12.5x, assuming you use a discount rate of 6.8%.
Given the current share price of $315.09, the analyst price target of $370.44 is 14.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Elevance Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ELV: Margin Recovery Will Drive Upside Despite ACA Headwinds And Premium Increases